To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Unknown 400 enrolled Sun Yat-sen University Eighth Affiliated Hospital, Sun Yat-sen University · collab First People's Hospital of Foshan · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is to guide clinical cure of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon gene mutation (IFNA2p.Ala120Thr) and interferon-stimulated genes (ISGs) detection gene spectrum.

Timeline

Start: 2018-12-01
Primary completion: 2023-12-30
Completion: 2024-12-30

Publications

Chen X, Zhang B, Song X, Qian T, Zheng X, Zhang Y, Xu W, Gao Z, Peng L, Xie C. Serum sPD-1 and sPD-L1 as predictive biomarkers for HBsAg clearance in HBeAg-negative CHB patients undergoing IFN-based therapy. Aliment Pharmacol Ther. 2024 Sep;60(5):593-603. doi: 10.1111/apt.18131. Epub 2024 Jun 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	—
Background	Entecavir	Small molecule	0.5 mg	—

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Summary

Timeline

Publications

Drugs

Indications